Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00061659 | Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma | PHASE2 | COMPLETED | 88 | — | — | May 1, 2003 | Apr 1, 2006 | Nov 29, 2007 | 5 | United States |
| Name | Type | Description |
|---|---|---|
| ABT-510 - Thrombospondin-1 mimetic | DRUG | - |
Inclusion Criteria A subject will be eligible for study participation if all of the following criteria are met: * The subject is at least 18 years of age. * The subject has histologically confirmed high grade locally advanced or metastatic soft tissue sarcoma (excluding Ewings sarcoma and chondros...